Oxford Nanopore Targets mRNA Therapeutic Quality Control
Oxford Nanopore is reportedly pivoting to productize its technology for the quality control of mRNA therapeutics. The strategy aims to replace current fragmented, multi-platform QC workflows with a single, unified nanopore sequencing platform. This move addresses a significant bottleneck in mRNA and viral vector manufacturing, where QC and batch release are often time-consuming.
Current quality control for mRNA therapeutics relies on a suite of separate analytical techniques, including capillary gel electrophoresis (CGE) for integrity, and various forms of chromatography (HPLC) and mass spectrometry to assess capping efficiency and poly(A) tail length. This multi-platform approach creates data silos and complicates the validation process required in GMP environments. Oxford Nanopore's technology enables direct RNA sequencing, which analyzes native RNA molecules without conversion to cDNA or PCR amplification. This avoids biases and errors introduced by reverse transcriptase enzymes and allows for the characterization of full-length mRNA transcripts in a single read, providing a complete picture of the molecule's integrity. A single nanopore sequencing run can assess multiple critical quality attributes (CQAs) simultaneously. This includes verifying the complete sequence, precisely measuring the length of the poly(A) tail, and directly detecting chemical modifications like N1-methylpseudouridine that are crucial for efficacy and reduced immunogenicity. The real-time data streaming from nanopore devices can reduce QC analysis from days to hours, accelerating batch release. To this end, Lonza and Oxford Nanopore are collaborating to bring direct mRNA sequencing to regulated manufacturing environments, aiming to establish it as a new standard for identity and integrity testing. This long-read sequencing approach has direct parallels in viral vector manufacturing. Gene therapy developers use long-read platforms to sequence the full-length AAV genome, verifying the integrity of inverted terminal repeats (ITRs) and identifying unwanted truncations or encapsidated host-cell DNA impurities. Consolidating QC onto one platform creates a unified data stream, simplifying the architecture for digital twins and bioprocess optimization. This rich, real-time data is well-suited for machine learning models that can predict batch success, automate process control, and support a proactive "Quality by Design" framework in a GMP setting.
